Literature DB >> 23967751

Treatment of recalcitrant chronic urticaria with nonsedating antihistamines: is there evidence for updosing?

M Sánchez-Borges1, F Caballero-Fonseca, A Capriles-Hulett.   

Abstract

Nonsedating antihistamines are the first-choice treatment for all forms of urticaria. In patients with recalcitrant urticaria who do not respond to conventional doses of antihistamines, current guidelines recommend increasing doses by up to 4 times in order to obtain better control of the disease. Although few studies have been conducted, there are convincing data from controlled trials for cetirizine, levocetirizine, and desloratadine that support the use of increased doses of such drugs in unresponsive patients. The use of higher doses of antihistamines has not been associated with increased adverse effects or somnolence. More studies with other second-generation antihistamines are required in order to improve the treatment of patients with severe, recalcitrant urticaria.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23967751

Source DB:  PubMed          Journal:  J Investig Allergol Clin Immunol        ISSN: 1018-9068            Impact factor:   4.333


  10 in total

1.  Management of chronic spontaneous urticaria in the elderly.

Authors:  Maria Teresa Ventura; Nicoletta Cassano; Paolo Romita; Michelangelo Vestita; Caterina Foti; Gino Antonio Vena
Journal:  Drugs Aging       Date:  2015-04       Impact factor: 3.923

2.  Insights and advances in chronic urticaria: a Canadian perspective.

Authors:  Gordon Sussman; Jacques Hébert; Wayne Gulliver; Charles Lynde; Susan Waserman; Amin Kanani; Moshe Ben-Shoshan; Spencer Horemans; Carly Barron; Stephen Betschel; William H Yang; Jan Dutz; Neil Shear; Gina Lacuesta; Peter Vadas; Kenneth Kobayashi; Hermenio Lima; F Estelle R Simons
Journal:  Allergy Asthma Clin Immunol       Date:  2015-02-11       Impact factor: 3.406

Review 3.  Management of urticaria: not too complicated, not too simple.

Authors:  M Ferrer; J Bartra; A Giménez-Arnau; I Jauregui; M Labrador-Horrillo; J Ortiz de Frutos; J F Silvestre; J Sastre; M Velasco; A Valero
Journal:  Clin Exp Allergy       Date:  2015-04       Impact factor: 5.018

Review 4.  Chronic urticaria in adults: state-of-the-art in the new millennium.

Authors:  Paulo Ricardo Criado; Roberta Facchini Jardim Criado; Celina Wakisaka Maruta; Vitor Manoel Silva dos Reis
Journal:  An Bras Dermatol       Date:  2015 Jan-Feb       Impact factor: 1.896

5.  Comparative efficacy of non-sedating antihistamine updosing in patients with chronic urticaria.

Authors:  Mario Sánchez-Borges; Ignacio Ansotegui; Jorge Montero Jimenez; Maria Isabel Rojo; Carlos Serrano; Anahí Yañez
Journal:  World Allergy Organ J       Date:  2014-11-26       Impact factor: 4.084

6.  Clinical characteristics and epidemiology of chronic urticaria: a nationwide, multicentre study on 1091 patients.

Authors:  Alina Jankowska-Konsur; Adam Reich; Jacek Szepietowski
Journal:  Postepy Dermatol Alergol       Date:  2019-05-14       Impact factor: 1.837

7.  High-dose levocetirizine for the treatment of refractory chronic spontaneous urticaria and the effect on the serum inositol triphosphate level.

Authors:  Xianqiong Huang; Zhaoyang Li; Renshan Sun
Journal:  J Int Med Res       Date:  2019-07-25       Impact factor: 1.671

8.  A Comparative, Three-Arm, Randomized Clinical Trial to Evaluate the Effectiveness and Tolerability of Bilastine vs Fexofenadine vs Levocetirizine at the Standard Dose and Bilastine vs Fexofenadine at Higher Than the Standard Dose (Up-Dosing) vs Levocetirizine and Hydroxyzine (in Combination) in Patients with Chronic Spontaneous Urticaria.

Authors:  Bela Shah; Dhiraj Dhoot; Ankita Choudhary; Neha Jangid; Deval Mistry; Shikha Shah; Shruti Kamat; Hanmant Barkate
Journal:  Clin Cosmet Investig Dermatol       Date:  2022-02-18

9.  Cetirizine for the treatment of allergic diseases in children: A systematic review and meta-analysis.

Authors:  Pengxiang Zhou; Qiong Jia; Zhenhuan Wang; Rongsheng Zhao; Wei Zhou
Journal:  Front Pediatr       Date:  2022-08-25       Impact factor: 3.569

10.  Therapeutic effect of Bacillus Calmette-Guerin polysaccharide nucleic acid on mast cell at the transcriptional level.

Authors:  Siyu Yan; Runqiu Liu; Manyun Mao; Zhaoqian Liu; Wei Zhang; Yi Zhang; Jie Li; Cong Peng; Xiang Chen
Journal:  PeerJ       Date:  2019-08-21       Impact factor: 2.984

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.